Michael is the global head of risk and compliance at ZS, helping clients unlock a new level of innovation, performance and patient outcomes by better navigating risk. Michael has over 25 years of experience working in health care and life sciences sectors as a legal and compliance leader.
For over 10 years, Michael was the vice president of ethics and compliance officer at GlaxoSmithKline (GSK) and a member of U.S. and global commercial leadership teams. Michael led and delivered competitive practices that drove measurable positive impact to GSK’s reputation and risk mitigation, while enabling strong business performance, effective collaboration between commercial and medical teams, increased employee engagement, and improved patient health outcomes.
Michael continues to be an invited speaker at many industry conferences and events and has served in leadership roles for the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Pharmaceutical Compliance Forum (PCF).
Prior to GSK, Michael served in various leadership roles at Novartis, where he was sought to design, implement, and lead the first global ethics and compliance program for its oncology enterprise after he successfully developed the ethics and compliance program for the U.S. pharmaceuticals business. Michael was also a director in PricewaterhouseCoopers’ global pharmaceutical and health sciences practice where he advised more than 24 life sciences companies on how to manage risk, be competitive, and develop an ethical corporate culture. Michael is also a former senior counsel with the Office of Inspector General (OIG) of the U.S. department of health and human services, where he was recruited to help develop strategic initiatives for the OIG and practical guidance for the healthcare industry. He was previously an Adjunct Professor at Seton Hall Law School teaching healthcare fraud and abuse law.
Michael holds a J.D. degree from New York Law School and a B.S. from the State University of New York at Albany.
How NY Gov. Andrew Cuomo Combined Behavioral Science and Leadership to Battle COVID-19
June 23, 2020 | type:article